Retatrutide

Retatrutide activates three receptor systems simultaneously. GLP-1 receptor activation slows gastric emptying, reduces appetite signaling in the hypothalamus, and improves insulin sensitivity — the same pathway that made semaglutide the most prescribed drug in modern medicine. GIP receptor activation amplifies the GLP-1 effect and improves adipocyte function, accelerating fat clearance from tissue. Glucagon receptor activation drives energy expenditure directly, increasing fat oxidation in the liver and adipose tissue even at rest.

The compounded effect is not additive — it is synergistic. Each receptor system amplifies the others. In Phase 2 trials, Retatrutide produced greater body weight reduction than any GLP-1 or dual agonist at comparable doses. For companion animals carrying excess weight — a condition affecting over 60% of dogs and 50% of cats — this triple mechanism addresses the full metabolic picture in a single weekly injection.

In the brain, GLP-1 receptors are expressed throughout the hippocampus, prefrontal cortex, and dopaminergic pathways. Activation of these receptors reduces neuroinflammation, upregulates BDNF (brain-derived neurotrophic factor), and restores the drive and engagement that disappears in metabolically impaired animals. The playful animal returns — not as a secondary effect, but as a direct consequence of what this receptor does when it is activated.